C4 Therapeutics, Inc
NASDAQ:CCCC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C4 Therapeutics, Inc
NASDAQ:CCCC
|
US |
|
Meko AB
F:1OM
|
SE |
|
F
|
F5 Inc
XMUN:FFV
|
US |
|
C
|
China Everbright Ltd
F:EVI
|
HK |
|
F
|
Fresenius SE & Co KGaA
XMUN:FRE
|
DE |
|
C
|
China Reinsurance (Group) Corp
F:C53
|
CN |
|
Kering SA
F:PPXB
|
FR |
|
C
|
China Everbright Ltd
XMUN:EVI
|
HK |
|
G
|
General Dynamics Corp
XMUN:GDX
|
US |
|
E
|
Electromagnetic Geoservices ASA
XMUN:E2M
|
NO |
|
K
|
Kering SA
XMUN:PPX
|
FR |
Intrinsic Value
Is CCCC undervalued or overvalued?
See the intrinsic value estimate for C4 Therapeutics, Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What C4 Therapeutics Does
C4 Therapeutics is a drug-development company focused on targeted protein degradation. Instead of trying to block a disease-causing protein, it designs small-molecule medicines that tag that protein for removal by the cell’s own cleanup system. Its main work is in oncology, where it builds drug candidates aimed at cancers driven by hard-to-treat proteins.
- Headquarters
- United States of America US
- Employees
- 104
- IPO date
- Oct 2, 2020
Earnings Waterfall
C4 Therapeutics, Inc
The intrinsic value for C4 Therapeutics, Inc (CCCC) under the Base Case is hidden USD.
Compared with the current market price of 3.21 USD, the stock appears hidden.
